Capstone Triton Financial Group LLC Acquires 302 Shares of Abbott Laboratories (NYSE:ABT)

Capstone Triton Financial Group LLC lifted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 1.5% during the 2nd quarter, Holdings Channel.com reports. The firm owned 20,401 shares of the healthcare product maker’s stock after purchasing an additional 302 shares during the period. Abbott Laboratories comprises 1.5% of Capstone Triton Financial Group LLC’s portfolio, making the stock its 20th largest holding. Capstone Triton Financial Group LLC’s holdings in Abbott Laboratories were worth $2,120,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in ABT. Gilbert & Cook Inc. raised its stake in shares of Abbott Laboratories by 17.4% in the fourth quarter. Gilbert & Cook Inc. now owns 7,556 shares of the healthcare product maker’s stock worth $832,000 after acquiring an additional 1,120 shares during the last quarter. Accretive Wealth Partners LLC increased its holdings in shares of Abbott Laboratories by 1.2% in the fourth quarter. Accretive Wealth Partners LLC now owns 13,322 shares of the healthcare product maker’s stock valued at $1,466,000 after purchasing an additional 152 shares in the last quarter. Aveo Capital Partners LLC raised its position in Abbott Laboratories by 13.3% in the 4th quarter. Aveo Capital Partners LLC now owns 3,525 shares of the healthcare product maker’s stock worth $388,000 after purchasing an additional 413 shares during the last quarter. Gryphon Financial Partners LLC lifted its holdings in Abbott Laboratories by 3.5% during the 4th quarter. Gryphon Financial Partners LLC now owns 111,176 shares of the healthcare product maker’s stock worth $12,252,000 after buying an additional 3,767 shares in the last quarter. Finally, TrinityPoint Wealth LLC boosted its position in Abbott Laboratories by 1.8% in the 4th quarter. TrinityPoint Wealth LLC now owns 21,247 shares of the healthcare product maker’s stock valued at $2,339,000 after buying an additional 376 shares during the last quarter. 75.18% of the stock is owned by institutional investors.

Insider Activity

In related news, CEO Robert B. Ford sold 141,679 shares of the firm’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $116.41, for a total transaction of $16,492,852.39. Following the sale, the chief executive officer now directly owns 220,059 shares in the company, valued at $25,617,068.19. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 1.10% of the company’s stock.

Wall Street Analyst Weigh In

ABT has been the subject of a number of recent research reports. Royal Bank of Canada restated an “outperform” rating and set a $125.00 target price on shares of Abbott Laboratories in a research report on Tuesday, June 4th. Citigroup upped their target price on shares of Abbott Laboratories from $119.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Barclays lifted their price target on shares of Abbott Laboratories from $140.00 to $143.00 and gave the stock an “overweight” rating in a research report on Monday, July 29th. The Goldman Sachs Group assumed coverage on shares of Abbott Laboratories in a report on Thursday, May 30th. They issued a “buy” rating and a $121.00 price objective on the stock. Finally, Evercore ISI lowered their target price on shares of Abbott Laboratories from $125.00 to $120.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $123.33.

Abbott Laboratories Price Performance

Shares of ABT stock opened at $113.69 on Friday. The company has a quick ratio of 1.18, a current ratio of 1.68 and a debt-to-equity ratio of 0.33. Abbott Laboratories has a 12-month low of $89.67 and a 12-month high of $121.64. The firm has a fifty day moving average of $110.50 and a 200-day moving average of $108.60. The firm has a market capitalization of $197.78 billion, a price-to-earnings ratio of 35.42, a price-to-earnings-growth ratio of 2.90 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, July 18th. The healthcare product maker reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.04. The firm had revenue of $10.38 billion during the quarter, compared to analysts’ expectations of $10.37 billion. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.65%. The company’s revenue was up 4.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.08 earnings per share. On average, equities research analysts forecast that Abbott Laboratories will post 4.66 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, November 15th. Shareholders of record on Tuesday, October 15th will be issued a dividend of $0.55 per share. The ex-dividend date of this dividend is Tuesday, October 15th. This represents a $2.20 annualized dividend and a yield of 1.94%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 68.54%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.